Janux Therapeutics, Inc. Current Liabilities
Janux Therapeutics, Inc. (JANX) had Current Liabilities of $60.15 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $60.15M.
- 2026-03-31: Liabilities, Current $58.91M.
- 2025-12-31: Liabilities, Current $25.00M.
- 2025-09-30: Liabilities, Current $27.83M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $60.15M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $58.91M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $25.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $27.83M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $21.38M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $17.50M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $17.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $17.17M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $11.54M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $10.61M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $13.03M 10-K · filed 2025-02-27 |
| 2023-09-30 | $14.47M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $17.90M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $16.11M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $16.51M 10-K · filed 2024-03-08 |
| 2022-09-30 | $16.34M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $12.99M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $12.52M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $12.80M 10-K · filed 2023-03-10 |
| 2021-09-30 | $12.47M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $9.21M 10-Q · filed 2021-08-10 |
| 2020-12-31 | $3.18M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |